Systemic Absorption of Oxylanthanum Carbonate is Minimal in Preclinical Models
Pramod Gupta,Atul Khare,Guru Reddy
DOI: https://doi.org/10.1007/s11094-024-03230-x
2024-10-19
Pharmaceutical Chemistry Journal
Abstract:Despite the widespread use of phosphate binders, hyperphosphatemia remains a critical health issue in the United States, possibly due to negative patient experiences (e.g., tablet intake convenience), resulting in poor compliance with labeled dosing schedules. Oxylanthanum carbonate is a novel molecule that uses a proprietary nanoparticle technology to deliver lanthanum in a smaller mass, creating significantly smaller, easier-to-swallow tablets. Two animal models evaluated the systemic absorption of oxylanthanum carbonate administered as daily oral doses for 6 weeks. Both the rat and dog models included 4 dose groups: 0, 200, 600, and 2,000 mg oxylanthanum carbonate/kg/day. Serum concentrations of lanthanum from blood samples were analyzed using high-resolution Inductively Coupled Argon Plasma Mass Spectroscopy (ICP-MS). The limit of quantification (LLOQ) was 0.5 ng/mL. Pharmacokinetic parameters were determined by noncompartmental methods. Overall, serum lanthanum concentrations were low: 43.3% and 46.8% of total samples were below the LLOQ on Day 1 for rats and dogs, respectively. Lanthanum exposure generally increased in approximate proportion to the dose in rats and less than proportion to the dose in dogs. In rats taking 2,000 mg, the mean times to maximum concentration were 12 and 8 hours after a single dose and repeated dosing, respectively. These same parameters were 6.6 and 10.3 hours for dogs taking 2,000 mg. Overall, serum lanthanum concentrations were low, and almost 50% of the samples were below the LLOQ, indicating minimal systemic absorption. This may translate to low systemic toxicity in the target population of patients with hyperphosphatemia.
pharmacology & pharmacy,chemistry, medicinal